We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSN icon
301
Tyson Foods
TSN
$20.4B
– –
-7,701
Closed -$459K
VSTM icon
302
Verastem
VSTM
$592M
– –
-1,364,000
Closed -$4.08M
W icon
303
Wayfair
W
$14.6B
– –
-55,000
Closed -$3.09M
WINT
304
DELISTED
Windtree Therapeutics
WINT
– –
-3,140
Closed -$375K
WKSP icon
305
Worksport
WKSP
$10.5M
– –
-299,300
Closed -$1.28M
WYNN icon
306
Wynn Resorts
WYNN
$10.6B
– –
-100,887
Closed -$9.67M
XNCR icon
307
Xencor
XNCR
$1.55B
– –
-478,000
Closed -$9.61M
XRT icon
308
State Street SPDR S&P Retail ETF
XRT
$327M
– –
-8,459
Closed -$657K
NEUP
309
Neuphoria Therapeutics
NEUP
$20.6M
– –
-132,750
Closed -$700K
ATXI
310
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
– –
-115,000
Closed -$286K
TFFP
311
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
– –
-228,000
Closed -$458K
VCNX
312
DELISTED
Vaccinex, Inc. Common Stock
VCNX
– –
-164,000
Closed -$558K
DNMR
313
DELISTED
Danimer Scientific, Inc.
DNMR
– –
-269,700
Closed -$4.9M
PRMW
314
DELISTED
Primo Water Corporation
PRMW
– –
-8,005
Closed -$202K
PIXY
315
DELISTED
ShiftPixy, Inc. Common Stock
PIXY
– –
-36,077
Closed -$449K
AVGR
316
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
-81,000
Closed -$77K
STAF
317
DELISTED
Staffing 360 Solutions, Inc. Common Stock (DE)
STAF
– –
-68,000
Closed -$93.2K
TTOO
318
DELISTED
T2 Biosystems, Inc
TTOO
– –
-1,396,000
Closed -$2.75M
CYTO
319
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-101,444
Closed -$61.9K
APTO
320
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-62,933
Closed -$776K
AIM
321
AIM ImmunoTech
AIM
$7.91M
– –
-43,343
Closed -$1.17M
9 10 11 12
13

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.